AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
AbbVie (NYSE: ABBV) reported Q1 EPS of $1.87, $0.08 better than the analyst estimate of $1.79. Revenue for the quarter came in at $7.93 billion versus the consensus estimate of $7.6 billion.
GUIDANCE:
AbbVie sees FY2018 EPS of $7.66-$7.76, versus the consensus of $7.54.
The company also plans to commence a tender offer to purchase for cash up to $7.5 billion in value of shares of its common stock through a modified "Dutch auction" tender offer at a specified price range to be determined. AbbVie expects to commence the tender offer as early as May 1, 2018.
The tender offer forms a part of AbbVie's $10 billion stock repurchase program announced on February 15, 2018.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Universal Logistics Holdings, Inc. (ULH) Tops Q1 EPS by 136c
- Tenaris SA (TS) Tops Q1 EPS by 22c; offers outlook
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Stock BuybacksRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!